Nureca Limited Q3 FY26 Concall Decoded:Revenue up 27%, EBITDA explodes 3x, PAT turns profitable — D2C flexing hard while offline is still warming up.
1. Opening Hook
While most smallcaps are busy blaming demand, inflation, or planets in retrograde, Nureca quietly decided to fix its own house. No drama, no debt restructuring sob story — just cold, boring execution.
Q3 FY26 was one of those quarters where numbers do all the talking, and management mostly nods along. EBITDA woke up from a two-year nap, PAT finally crossed into positive territory, and the balance sheet stayed cleaner than a hospital OT.
This concall isn’t about “jam tomorrow.” It’s about D2C today, manufacturing tomorrow, and connected health someday soon.
Read on — because this is one of those rare consumer-tech plays where marketing noise is finally converting into actual profits.
2. At a Glance
Revenue up 27% YoY – Online sales doing what offline dreams of.
EBITDA up 314% YoY – Operating leverage entered the chat.
EBITDA margin ~13% – Finally behaving like a brand, not a trader.
PAT ₹37 Cr vs loss last year – Losses officially evicted.
90% revenue from online – Digital-first, not digital-theory.
Debt-free balance sheet – Peace of mind premium included.
3. Management’s Key Commentary
“We are a digital-first healthcare company with more than 90% revenue online.” (Translation: Offline is optional, Amazon is mandatory 😏)
“Our EBITDA growth reflects scale benefits and cost discipline.” (Marketing ROI finally learned maths.)
“Nureca is debt-free and asset-light with strong liquidity.” (Sleep-at-night balance sheet.)
“Manufacturing at NTPL improves quality control and margins.” (Goodbye import dependency, hello gross margin expansion.)
“Dr Trust 360 transforms devices into a health ecosystem.” (Hardware + software = sticky customers.)
“Offline distribution is being restructured and standardized.” (Retail push… but without burning cash 🔥.)
4. Numbers Decoded
Metric
Q3 FY26
YoY
Edu Decode
Revenue (₹ Cr)
540
↑27%
Strong D2C demand
EBITDA (₹ Cr)
54
↑314%
Operating leverage unlocked
EBITDA Margin
~13%
↑
Brand phase begins
PAT (₹ Cr)
37
Turned positive
Loss era officially over
9M PAT (₹ Cr)
82
Massive jump
Structural improvement
This isn’t cost-cutting magic — it’s scale kicking in.
